161 related articles for article (PubMed ID: 8527351)
1. Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. The Canadian Multicenter Diltiazem-CD Hypertension Trial Group.
Ruddy TD; Wright JM; Savard D; Handa SP; Chockalingam A; Boulet AP
Cardiovasc Drugs Ther; 1995 Jun; 9(3):413-20. PubMed ID: 8527351
[TBL] [Abstract][Full Text] [Related]
2. 24 hour blood pressure control with once-daily versus twice-daily formulations of diltiazem.
Ruddy TD; Wright JM; Savard D; Handa SP; Chockalingam A; Fischer L; Boulet AP
Cardiovasc Drugs Ther; 1995 Dec; 9(6):799-807. PubMed ID: 8850385
[TBL] [Abstract][Full Text] [Related]
3. 24-hour efficacy of once-daily diltiazem in essential hypertension.
Massie BM; Der E; Herman TS; Topolski P; Park GD; Stewart WH
Clin Cardiol; 1992 May; 15(5):365-8. PubMed ID: 1623657
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive efficacy of optimally titrated doses of once-daily sustained-release diltiazem: a placebo-controlled trial. DILPLACOMP Study Group.
Ollivier JP; Wajman A; Stalla-Bourdillon A
Cardiology; 1995; 86(6):481-7. PubMed ID: 7585759
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of blood pressure response to the combination of enalapril (single dose) and diltiazem ER (four different doses) in systemic hypertension.
Applegate WB; Cohen JD; Wolfson P; Davis A; Green S
Am J Cardiol; 1996 Jul; 78(1):51-5. PubMed ID: 8712118
[TBL] [Abstract][Full Text] [Related]
6. Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product.
White WB; Lacourciere Y; Gana T; Pascual MG; Smith DH; Albert KS
Am Heart J; 2004 Oct; 148(4):628-34. PubMed ID: 15459593
[TBL] [Abstract][Full Text] [Related]
7. Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD. Mibefradil Hypertension Study Group.
Bittar N
Clin Ther; 1997; 19(5):954-62. PubMed ID: 9385483
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and tolerability of an angiotensin converting enzyme inhibitor (lisinopril) versus a calcium channel antagonist (diltiazem SR) in the treatment of moderate to severe hypertension.
Weir MR; Fagan T; Chrysant S; Flamenbaum W; Kaihlanen PM; Lueg M; Anzalone D
J Hum Hypertens; 1994 Jul; 8(7):531-7. PubMed ID: 7932518
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of once-daily diltiazem in patients with stable angina pectoris switched from twice-daily diltiazem.
Savard D; Lenis J; Juneau M; Jacob C; Boulet AP
J Cardiovasc Pharmacol; 1995 Jul; 26(1):85-9. PubMed ID: 7564371
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with a once-daily, extended-release formulation of diltiazem in the treatment of hypertension.
Graney WF
Am J Med; 1992 Aug; 93(2A):56S-64S. PubMed ID: 1519637
[TBL] [Abstract][Full Text] [Related]
11. Once daily compared with twice daily administration of slow-release diltiazem as monotherapy for hypertension.
Nikkilä M; Inkovaara J; Heikkinen J
Ann Med; 1991 Apr; 23(2):141-5. PubMed ID: 2069791
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive efficacy and tolerability of once-daily sustained-release diltiazem alone and in combination with ramipril in hypertension.
Tuteja R; Swarup D; Saxena GN; Bhandari S; Sharma P
J Assoc Physicians India; 1999 Oct; 47(10):962-5. PubMed ID: 10778687
[TBL] [Abstract][Full Text] [Related]
13. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive efficacy and safe use of once-daily sustained-release diltiazem in the elderly: a comparison with captopril. The Dilcacomp Study Group.
Nicaise J; Neveux E; Blondin P
J Int Med Res; 1995; 23(4):244-53. PubMed ID: 7589767
[TBL] [Abstract][Full Text] [Related]
15. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension.
Weir MR; Weber MA; Punzi HA; Serfer HM; Rosenblatt S; Cady WJ
J Hum Hypertens; 1992 Apr; 6(2):133-8. PubMed ID: 1597846
[TBL] [Abstract][Full Text] [Related]
16. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
[TBL] [Abstract][Full Text] [Related]
17. Transdermal clonidine as an adjunct to sustained-release diltiazem in the treatment of mild-to-moderate hypertension.
Lueg MC; Herron J; Zellner S
Clin Ther; 1991; 13(4):471-81. PubMed ID: 1933999
[TBL] [Abstract][Full Text] [Related]
18. The use of confidence intervals to describe the precision of trough/peak ratios for diltiazem CD in the treatment of hypertension.
Meeves SG; Park GD
J Clin Pharmacol; 1994 Mar; 34(3):231-5. PubMed ID: 8021331
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-h ambulatory monitoring.
Watts RW; Wing LM
Blood Press; 1998 Jan; 7(1):25-30. PubMed ID: 9551874
[TBL] [Abstract][Full Text] [Related]
20. Once daily perindopril versus slow release diltiazem in the treatment of mild to moderate essential hypertension. Canadian Study Group on Perindopril.
Can J Cardiol; 1994 Nov; 10 Suppl D():8D-12D. PubMed ID: 7954041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
